EPHB2 and T-cell non-Hodgkin lymphoma: Pralatrexate, a T-cell lymphoma medication, was identified via virtual screening to potentially bind to the EphB2-ephrinB2 complex, where the expression of the complex is associated with cancer cells as shown in Fig. 7.